2020 wins top of the froths for biotech stocks
It's official: dramatic share price jumps in response to clinical data have become more common.
Astounding success greets newly public device makers
2020 was a bountiful year for medtechs making their public debut, with one group, Inari Medical, more than quadrupling in value.
A tale of two Covids for smaller device makers
The pandemic provided the best and worst of times for smid-cap medtechs.
Telemedicine and the “Zoom effect” boost big-cap medtech
In the second half of 2020 medtech began a tentative – and possibly short-lived – recovery.
Biopharma shares keep riding the Covid wave
The pandemic remains the dominant storyline for drug stocks at the nine-month mark, with Vertex and Horizon rare non-Covid-related risers.
